86129-31-9

Upstream product

• 4530-20-5 BOC-glycine 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 2130-96-3 O-benzyl-N-tert-butoxycarbonyl-L-tyrosine 
• 23680-31-1 BOC-O-benzyl-L-serine 
• 77614-16-5 dermorphin 
• 830-03-5 4-nitrophenol acetate 

Relevant academic research and scientific papers

Synthesis and activity of dermorphin-growth hormone releasing factor hybrid peptides

Dermorphin- growth hormone releasing factor (GRF) hybrid peptides (Y-Tyr-D-Ala-Xaa-Gly-Tyr-Pro-Ser-NH2) were synthesized and tested for opioid activity and their ability to stimulate growth hormone (GH) secretion. The substitution of Phe3

Structure-Activity Studies of Dermorphin. Synthesis and Some Pharmacological Data of Dermorphin and Its 1-Substiituted Analogues

Dermorphin and its analogues substituted at position 1 by N-acetyltyrosine, O-methyltyrosine, phenylalanine, D-phenylalanine, or alanine were obtained by solid-phase peptide synthesis.Their pharmacological effects were studied in vitro by the guinea pig ileum method and in vivo by the hot plate method, and the results were compared with those of morphine.The most pronounced activity was shown for dermorphin.A radioreceptor study showed a moderate affinity of dermorphin and its Tyr(Me)1 analogue for the opiate receptor sites from striatal homogenates.